期刊文献+

骨代谢生化指标在乳腺癌骨转移中的意义 被引量:5

The significance of bone metabolic markers in bone metastasis of breast cancer
原文传递
导出
摘要 乳腺癌是一种容易引起骨转移的女性常见的恶性肿瘤,其机制以溶骨性骨转移为主。在正常骨代谢中,由成骨细胞介导的骨形成作用和由破骨细胞介导的骨吸收作用之间呈动态平衡,而发生骨转移时,转移的肿瘤细胞可打破这种平衡,并引起相应骨代谢指标的改变,而这种改变可通过血液及尿液化验检测。近年来研究的骨特异性标记物可总结为骨吸收标记物及骨形成标记物,前者包括抗酒石酸酸性磷酸酶(TRACP)异构体5b,Ⅰ型胶原吡啶交联终肽(ICTP),Ⅰ型胶原蛋白交联氨基末端肽和羧基末端肽(NTx/CTx)及吡啶酚(PYD)和脱氧吡啶酚(D-PYD)。后者包括骨特异性碱性磷酸酶(BAP),Ⅰ型前胶原氨基端前肽(PINP)和Ⅰ型前胶原羧基端前肽(PICP)、骨唾液酸蛋白(BSP)、骨钙素(OC)等。这些实验室检测为早期乳腺癌骨转移的诊断提供了更多的依据。 Breast cancer ranks among the most prevalent malignancies in women to cause bone metastasis, which the main mechanism is osteolytic bone metastasis. There is a balance between the formation of new bone by osteoblasts and the resorption of old bone by osteoclasts in normal bone metabolism. Cancer cells within bone marrow interfere this balance and cause the change of the corresponding bone metabolism indicators, and this change can be detected through blood or ufine. Bone-specific markers researched recently can be summarized as bone resorption markers and bone formation markers, the former include tartrate-resistant acid phosphatase 5b( TracpSb), carboxy-terminal telopeptide of type Ⅰ collagen (ICTP), N-terminal and C-terminal cross-linked telopeptide of type Ⅰ collagen (NTx/CTx), pyridinoline(PYD) and droxypyridinoline (D-PYD), while the latter consist of bone isoenzyme of alkaline phosphatase( BAP), N-terminal propeptide of type Ⅰ procolⅠlagen( PINP), carboxy-terminal propeptide of type Ⅰ procollagen ( PICP), bone sialoprotein(BSP), osteocalcin (OC), et al. These laboratory tests can provide more evidences for an early diagnosis of breast cancer with bone metastases.
出处 《中国实用医刊》 2013年第12期117-119,共3页 Chinese Journal of Practical Medicine
关键词 乳腺癌 骨转移 生化指标 Breast cancer Bone metastasis Bone metabolic markers
  • 相关文献

参考文献20

  • 1Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities[J]. Nature Reviews Cancer,2002,2(8) :584-593.
  • 2Chen C. An approach to the relevance between variations in hormone secretion and the incidence of hyperplasia of mammary glands and mammary cancer[ R]. 2004 ,ISPO Meeting.
  • 3Berruti A, Dogliotti L, Gorzeguo G, et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases [ J ]. Clin Chem, 1999,45 ( 8ptl ) : 1240-1247.
  • 4Pratap J, Javed A, Languino LR, et al. The Runx2 osteogenic tran- scription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion [J]. Mol Cell Bid, 2005,25 (19) : 8581-8591.
  • 5Halleen JM, Alatalo SL, Janckila AJ, et al. Tartrate-resistant acid phosphatase 5 b is a specific and sensitive marker of bone re- sorption[ J]. Anticancer Res,2003,23(2A) : 1027-1029.
  • 6Halleen JM, Alatalo SL, Suominen H, et al. Tartrate-resistant acid phosphatase 5b : a novel serum marker of bone resorption[ J]. JBMR, 2000,15 (7) : 1337-1345.
  • 7Takahashi S. Evaluation of cancer-induced bone diseases by bone metabolic marker[J]. Clin Calcium,2006,16(4) : 581-590.
  • 8章火祥,谢鑫友,于小妹,钭春凤,王丽君.血清Ⅰ型胶原吡啶交联终肽、骨钙素在肿瘤骨转移中的应用[J].国际检验医学杂志,2008,29(11):983-985. 被引量:5
  • 9Maemura M,Iino Y, Yokoe T,et al. Serum concentration of pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with metastatic breast cancer[J]. Oncol Rep, 2000, 7(6) :1333-1338.
  • 10Izumi M, Nakanishi Y, Takayama K, et al. Diagnostic value of bone- turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma[ J]. Cancer,2001,19 (8) : 1487-1493.

二级参考文献15

  • 1孔清泉,屠重棋,窦青瑜,汪金平,孙天威.骨转换生化指标在诊断原发性肺癌骨转移中的应用[J].四川大学学报(医学版),2005,36(3):397-399. 被引量:8
  • 2Koizumi M, Ogata E. Bone metabolic markers as gauges of metastasis to bone:a review [J]. Ann Nucl Med, 2002, 16(3): 161-168.
  • 3Alatas F, Alatas O, Metintas M, et al. Usefulness of bone markers for detection of bone metastases in lung cancer patients [J]. Clin Biochem, 2002, 35(4): 293-296.
  • 4Kiuchi K, Ishikawa T, Hamaguchi Y, et al. Cross-linked colla- gen C- and N-telopeptides for an early diagnosis of bone metastasis from breast cancer [J]. Oncol Rep, 2002, 9(3): 595-958.
  • 5Ulrich U, Rhiem K, Schmolling J, et al. Cross-linked type I col lagen C- and N-telopeptides in women with bone metastases from breast cancer [J]. Arch Gynecol Obstet, 2001, 264 (4) : 186- 190.
  • 6Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer[J].J Clin Oncol, 2004, 22(14): 2942 -2953.
  • 7Zissimopoulos A, Petrakis G, Stellos K, et al. Procollagen-1, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer[J].Hell J Nucl Med, 2006,9 ( 1 ) : 60-64.
  • 8Koizumi M, Takahashi S, Ogata E. Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer[J]. Breast Cancer, 2003,10(1):21-27.
  • 9Ebert W, Muley T, Herb KP, et al. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients [J]. Anticancer Res, 2004, 24(5B) :3193 -3201.
  • 10Keskikuru R, Kataja V, Kosma VM, et al. Preoperative high type I collagen degrad- ation marker ICTP reflects advanced breast cancer[J]. Anticancer Res, 1999, 19(5C) : 4481.

共引文献16

同被引文献50

引证文献5

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部